MR/CT

Japan Approves Low-Dose MRI Contrast Agent Ambelvist

Bayer has received the first global approval for its low-dose MRI contrast agent Ambelvist™ (gadoquatrane) in Japan.

Detection Technology Introduces X-ACE HS Detectors for Next-Generation CT

Offering faster data acquisition, expanded slice coverage up to 64 slices, and improved low-dose performance.

Advancing Spectral CT: A First Clinical Experience with Philips Verida

Spectral imaging, faster workflows and lower radiation dose are shaping the next generation of CT diagnostics.

UChicago Medicine Expands Neurosurgery With Intraoperative MRI

UChicago Medicine has introduced intraoperative MRI technology to support complex neurosurgical procedures, enabling real-time imaging during surgery and enhancing precision, safety, and workflow efficiency.

AB-CT Launches Photon-Counting Breast CT in Australia with First Melbourne Installation

German MedTech firm installs its nu:view spiral breast CT at Malvern Breast Imaging, bringing compression-free 3D breast imaging to Australia for the first time.

Bayer Presents New Data for Contrast Agent Gadoquatrane from Phase III Program at ECR 2026

New analyses show Bayer’s investigational MRI contrast agent delivers non-inferior diagnostic performance while reducing gadolinium dose by 60%.

Bayer Presents Phase III Cardiac MRI Data for Low-Dose Gadoquatrane

Bayer has reported positive Phase III subgroup data for its investigational low-dose MRI contrast agent gadoquatrane in cardiac MRI. The results, presented at SCMR 2026, support efficacy and safety with a 60% reduction in gadolinium dose compared to standard macrocyclic agents.

Guerbet Highlights Centenary and Imaging Portfolio at ECR 2026

At ECR 2026 in Vienna, Guerbet will mark its 100th anniversary while presenting developments across contrast-enhanced MRI, real-world evidence, and international collaboration

Rewriting the Standard of Care: How Cardiac CTA Is Transforming Outcomes From Diagnosis to Prevention — and Toward Asymptomatic Screening

RSNA 2025 made one thing unmistakably clear: Cardiac CT angiography (CCTA) has reached a turning point—and it is beginning to redefine how we detect and prevent heart disease.

Bayer to Present Phase III Gadoquatrane Data at ECR 2026

Bayer will present new Phase III clinical data for its investigational low-dose MRI contrast agent gadoquatrane at ECR 2026 in Vienna.

Planmed XFI Weight-Bearing CT Earns CE MDR Certification

Planmed has received CE marking under the EU Medical Device Regulation (MDR) for its Planmed XFI weight-bearing cone-beam CT system.

NHS Fife Cuts MRI Scan Times Over 20% With Siemens AI

NHS Fife has implemented Siemens Healthineers’ Deep Resolve technology to shorten MRI scan times by more than 20%. The AI-based image reconstruction approach has reduced waiting times, and enabled nearly 1,900 additional MRI appointments within six months.

MRI Connectivity Patterns May Help Predict TBI Recovery

New research suggests that resting-state functional MRI performed shortly after traumatic brain injury may help predict long-term recovery. Specific brain connectivity patterns were found to be associated with functional outcomes six months after injury.

ASE Reviews 2025 Advocacy Priorities in Cardiovascular Imaging

The American Society of Echocardiography (ASE) has reviewed its healthcare advocacy activities in 2025, highlighting efforts related to Medicare reimbursement, workforce shortages, artificial intelligence policy, and federal research funding in cardiovascular imaging.

Bayer Expands Radiology Portfolio Into Diagnostic Tracers

Acquisition of AT-01 and AT-05 expands Bayer’s molecular imaging portfolio.

Bayer Reports Positive Pediatric Data for Low-Dose MRI Contrast Agent Gadoquatrane

Bayer has released late-breaking results from the QUANTI Pediatric study, showing that its investigational low-dose MRI contrast agent gadoquatrane met all primary and secondary endpoints in children.

Elucid Launches PlaqueIQ Software for Carotid Artery Analysis

Elucid has introduced PlaqueIQ, a CT-based image analysis software indicated for the carotid arteries, enabling precise quantification of plaque composition to help physicians assess stroke risk and personalize treatment.

Circular MRI Model Could Save Hospitals Over $500K Per Scanner

Adopting circular business models for MRI systems could reduce total ownership costs by up to 21% and cut emissions and material use significantly.

Innovating Cancer Care: Bayer’s Low-Dose Contrast Enhanced MRI

Advancing radiology for smart imaging

Transforming Prostate Care: Innovation and Progress through Partnership in Radiology

Two leading voices discuss how collaboration drives progress in oncologic imaging.

UK’s First Laser-Guided Photon-Counting CT Installed at NUH

Nottingham University Hospitals NHS Trust (NUH) has become the first site in the UK to install a photon-counting CT scanner with integrated laser-guided intervention.

Radiology network ARISTRA adopts AB-CT breast CT technology

MedTech company AB-CT – Advanced Breast-CT, developer of the world’s only photon-counting breast CT, has partnered with radiology network ARISTRA.

Radiology Staffing Shortages: U.S. vs. UK Approaches

High vacancy rates continue to affect imaging departments. Data highlights the scale of the workforce shortage and measures to address the challenge.

Post-COVID CT Guidelines by International Radiology Consensus

Standardized guidelines for CT imaging in patients with residual lung abnormalities after COVID-19

Pediatric Imaging Market to Double in Value Over Next Decade

The pediatric imaging market is expected to more than double in value by 2034, made possible by advances in low-dose and AI-powered imaging.

FDA Grants Clearance for DeepHealth’s TechLive™

DeepHealth has received FDA 510(k) clearance for TechLive™, a vendor-agnostic remote scanning solution.

Neuroradiology Enables Targeted Treatment for Pulse-Synchronous Tinnitus

Advances in imaging techniques improve diagnosis and therapy options for vascular-related tinnitus symptoms

Bayer files for EU approval of gadoquatrane

Submitted dose corresponds to 60% gadolinium reduction compared to standard macrocyclic agents

Bayer Submits MRI Contrast Agent Gadoquatrane for FDA Review

If approved, gadoquatrane would become the lowest-dose macrocyclic gadolinium-based contrast agent available in the U.S. market.

Siemens Healthineers Presents MAGNETOM Flow RT Pro Edition for Sustainable Magnetic Resonance Imaging in Radiation Therapy

Siemens Healthineers showcased its latest MRI system for radiation therapy at this year’s European Society for Radiotherapy and Oncology congress.

Bracco at ECR 2025: Innovations in Contrast Media and Sustainability

At ECR 2025, Bracco Imaging showcased two major developments aimed at improving contrast media efficiency, and improving patient safety.

Bracco brings actionable solutions for ‘Planet Radiology’ to ECR 2025

Fabio Tedoldi from Bracco Imaging shares some highlights of their collaboration with the Dutch company Zereau at ECR.

Bayer at ECR 2025: Shaping Radiology with Contrast & AI

At the ECR 2025 Bayer highlights the promising phase three trial data for the MRI contrast agent Gadoquatrane.

ECR 2025 Shines a Spotlight on Next-Generation Imaging Innovations

Esaote Group has drawn significant attention with its unveiling of their latest innovations, which integrate advanced artificial intelligence with cutting-edge hardware.

Positive results from Phase III study for Bayer’s investigational contrast agent gadoquatrane

BGF invests £6 million into Signify Research

Gadopiclenol received the JFR* 2024 Innovation Award

SIRM2024: Giovagnoni on Oncology and the Olympics

SIRM2024: Bracco on New Contrast & Trends in EMEA